Harbin Gloria Pharmaceuticals (also known as Gloria Pharmaceuticals), established in 2000, is a pharmaceutical company with R&D capabilities to develop therapeutics for pain, infectious disease and cancer.In July 2018, Harbin Gloria Pharmaceuticals planned to acquire a major stake in Hefei Tianmai Biotechnology for YEN 4 billion (US$600 million).In January 2015, Harbin Gloria Pharmaceuticals signed an equity transfer agreement with five of Shanxi Pude Pharmaceutical's sharehoplders to acquire 118 million shares, representing 85.01% of Pude Pharmaceutical's total shares, for RMB 2388.73 million (US $387.67 million). In May 2016, Harbin Gloria Pharmaceuticals signed an agreement with Shanxi C&Y Pharmaceutical to sell its rights of Shanxi Pude Pharmaceutical.In January 2014, Harbin Gloria Pharmaceuticals signed stock right transfer agreement with part of Shanghai Hotmed Sciences' shareholders. Harbin Gloria spent RMB 698 million (US $114.50 million) on purchasing 106 million sha